<DOC>
	<DOCNO>NCT00002124</DOCNO>
	<brief_summary>PART I : To evaluate safety , tolerance , efficacy , pharmacokinetics three fix dos delavirdine mesylate ( DLV ) combination zidovudine ( AZT ) versus AZT alone HIV-positive patient . PART II : To evaluate safety , tolerance , efficacy , pharmacokinetics ZDV plus 3TC without DLV versus ZDV plus DLV HIV-positive patient .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Dose Response Study Three Doses Delavirdine Mesylate ( U-90152S ) Combination With Zidovudine ( ZDV ) Versus ZDV Alone HIV-1 Infected Individuals With CD4 Counts 200-500mm3</brief_title>
	<detailed_description>PART I : Patients originally randomize receive ZDV plus DLV ( DLV 1 3 dos ) ZDV plus placebo . AS PER AMENDMENT 3/7/96 : PART II : Patients rerandomized PART I . Arm I : ZDV plus 3TC plus placebo . Arm II : ZDV plus 3TC plus DLV . Arm III : ZDV plus DLV ( DLV high dose original protocol ) . Arm IV : ZDV plus DLV ( change original ; treatment Arm III ) . AS PER AMENDMENT 1/24/97 : Approximately 450 patient enrol one 3 revise arm PART II . Half new patient anti-retroviral naive half anti-retroviral experienced .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 seropositivity . CD4 count 200500 cells/mm3 . No active acute ( onset within past month ) opportunistic infection active cryptococcosis , pneumocystis carinii , herpes zoster , histoplasmosis , cytomegalovirus ( CMV ) . Consent parent guardian le 18 year age . Understanding potential risk fetus relate study participation . Acceptable medical history , physical exam , EKG , chest xray screening . NOTE : Patients cutaneous Kaposi 's sarcoma require systemic therapy permit . PER AMENDMENT 3/7/96 : ZDV therapy 06 month prior study entry . ( Part II ) Prior Medication : Allowed : Prior AZT ( 6 month total ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active tuberculosis sensitive rifampin . Inability swallow numerous tablet . Clinically significant active acute medical problem , include progressive multifocal leukoencephalopathy , lymphoma , malignancy require systemic therapy . Clinically significant hypersensitivity piperazinetype drug ( e.g. , Antepar Stelazine ) . Grade 2 bad baseline organ function . NOTE : Hemophiliacs grade 2 bilirubin , alkaline phosphatase , SGOT , SGPT consider value stable past year . NOTE : Patients suspect Gilbert 's syndrome consider bilirubin grade 2 better . Patients follow prior condition exclude : History pancreatitis within past 2 year . History clinically significant nervous system muscle disease , seizure disorder , AIDS dementia , psychiatric disorder would preclude study compliance . History grade 2 bad peripheral neuropathy . Intolerance AZT previously treat patient . Prior Medication : Excluded : More 6 month total prior AZT . Any prior ddC , d4T , 3TC , ddI . Prior nonnucleoside reverse transcriptase inhibitor , include Ldrugs , nevirapine , TIBO , HEPT , delavirdine , atevirdine , alphaAPA . Other investigational antiretroviral medication ( include foscarnet ) immunomodulators ( include interferon ) within 21 day prior initial study drug dose . Prior prophylactic therapeutic HIV1 gp120 160 vaccine . Rifampin , rifabutin , astemizole , loratadine , terfenadine within 21 day prior initial study drug dose . Any unapproved investigational medication indication within 21 day prior initial study drug dose . Any enzymeinducing drug know affect cytochrome P450 3A , ( e.g. , ketoconazole , fluconazole , isoniazid , itraconazole , etc . ) within 21 day prior initial study drug dose . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1997</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>